Real-world Outcomes of Peripheral T-cell Lymphoma: A Multicenter Retrospective and Prospective Cohort Study

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

3000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-11-15

Study Completion Date

2035-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study aims to characterize the epidemiology, clinicopathologic features, and survival outcomes of Chinese patients with PTCL; to develop and validate prognostic models to this population; to compare the real-world effectiveness and safety of alternative therapeutic strategies; to elucidate molecular mechanisms underlying treatment resistance and relapse; to identify actionable targets and predictive biomarkers.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Radiotherapy Followed by Adjuvant Chemotherapy in NK/T-cell Lymphoma

NCT01667302

Extranodal NK/T-cell Lymphoma, Nasal Type

UNKNOWN PHASE2

A Phase I/II Study of Mitoxantrone Liposome Combined With Chidamide in Relapsed/Refractory Peripheral T-cell Lymphoma

NCT05527275

Relapsed and Refractory Peripheral T-cell Lymphoma

UNKNOWN PHASE1/PHASE2

Low-dose Radiotherapy Combined With Conventional Radiotherapy After Immunotherapy Failure

NCT05547282

Cancer Patients

UNKNOWN NA

IFN-γ Combined With T Cells in the Treatment of Refractory Malignant Pleural Effusion and Ascites

NCT05268172

Pleural Effusion, Malignant

RECRUITING PHASE1

Genotype-guided Treatment in Newly Diagnosed PTCL

NCT05675813

Peripheral T Cell Lymphoma

RECRUITING PHASE1/PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Due to disease heterogeneity and variability in clinical practice, establishing a large-scale Chinese PTCL database to characterize real-world treatment patterns and clinical outcomes is a critical undertaking. A retrospective cohort will define the clinical epidemiology of the disease, while a prospective cohort will delineate current treatment pathways and outcomes in routine practice and explore the molecular features of PTCL in the Chinese population, thereby providing evidence to support precision therapy.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Peripheral T-Cell Lymphoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Cohort A (Retrospective)

A retrospective cohort of cases diagnosed between 2010 and 2024, assembled from medical-record data.

Target enrollment: 1,300-1,500 patients.

Observational

Intervention Type OTHER

Observational

Cohort B (Prospective)

A prospective cohort of patients newly diagnosed between 2025 and 2030, ensuring ≥5-year follow-up for all survivors.

Target sample size: 1,000-1,500 cases, estimated from participating centers' annual diagnostic volumes over a 5-year accrual period. The cohort should be multidimensionally representative, including: (i) geographic coverage across North, East, South, Southwest, and Northeast China; (ii) hospital tiers with tertiary ("Class III Grade A") institutions as the core and selective inclusion of prefecture-level hospitals; and (iii) economic diversity spanning regions with differing levels of socioeconomic development.

Observational

Intervention Type OTHER

Observational

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Observational

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age ≥18 years, with a histopathologic diagnosis of PTCL (any subtype per WHO 2016 classification of hematolymphoid neoplasms).
* Cohort A: Patients diagnosed and treated at participating centers between 2010 and 2024.
* Cohort B: Patients newly diagnosed from October 2025 onward.
* Availability of basic diagnostic and treatment records .

Exclusion Criteria

* Indeterminate diagnosis or missing pathology report.
* Patients diagnosed at an outside institution who did not receive their primary treatment and follow-up at a participating center.
* Diagnoses of NK/T-cell lymphoma or primary cutaneous T-cell lymphomas.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No